JNJ-81201887

DRUG4 trials

Sponsors

Janssen - Cilag International, Janssen Research & Development, LLC

Conditions

Geographic AtrophyMacular Degeneration

Phase 2

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

CompletedNCT05811351

Janssen Research & Development, LLCGeographic Atrophy

Start: 2023-03-06End: 2026-02-23Updated: 2026-03-13

A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Active, not recruitingCTIS2022-500746-16-00

Janssen - Cilag InternationalGeographic Atrophy

Start: 2023-08-11Target: 118Updated: 2025-12-15

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

RecruitingNCT06635148

Janssen Research & Development, LLCGeographic Atrophy, Macular Degeneration

Start: 2024-09-19End: 2030-07-16Target: 274Updated: 2026-03-13

Long-term Extension Study for Participants with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies

RecruitingCTIS2022-500747-21-00

Janssen - Cilag InternationalGeographic Atrophy

Start: 2025-02-27Target: 120Updated: 2025-08-25